Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / articles / NKTX - What's Going With Cancer-Focused Nkarta Stock Today? | Benzinga

NKTX - What's Going With Cancer-Focused Nkarta Stock Today? | Benzinga

Nkarta Inc.

Nkarta Inc (NASDAQ: NKTX) received FDA clearance for its Investigational New Drug (IND) application to evaluate NKX019, its allogeneic, CD19-directed CAR NK cell therapy candidate, for lupus nephritis.

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by abnormal B cell function and autoantibody production and results in a range of clinical manifestations, including organ damage and an increased risk of death. 

Also Read: Full story available on Benzinga.com
Stock Information
Company Name: Nkarta Inc.
Stock Symbol: NKTX
Market: NASDAQ
Website: nkartatx.com
Menu
NKTX NKTX Quote NKTX Short NKTX News NKTX Articles NKTX Message Board
Get NKTX Alerts

News, Short Squeeze, Breakout and More Instantly...